Celcuity Stock Quote CELC - Stock Price, News, Charts, Message Board, Trades

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Current Price

18.79

Bid

18.46

Ask

19.50

Volume

459,815

17.51 Day's Range 18.85

8.389 52 Week Range 22.188

Market Cap

554.959M

Previous Close

17.77

Open

17.95

Last Trade

169800

18.79

(priorref)

Last Trade Time

Financial Volume

$ 8,295,532

VWAP

18.041

Average Volume (3m)

277,294

Shares Outstanding

31,230,085

Dividend Yield

PE Ratio

-9.20

Earnings Per Share (EPS)

-2.04

Revenue

Net Profit

-63.78M

Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered ... Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Show more

Sector

Medical Laboratories

Industry

Medical Laboratories

Website

www.celcuity.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Celcuity Inc is listed in the Medical Laboratories sector of the NASDAQ with ticker CELC. The last closing price for Celcuity was $17.77. Over the last year, Celcuity shares have traded in a share price range of $ 8.389 to $ 22.188.

Celcuity currently has 31,230,085 shares outstanding. The market capitalization of Celcuity is $554.96 million. Celcuity has a price to earnings ratio (PE ratio) of -9.20.

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.72	10.0761570006	17.07	18.85	16.62	350133	17.11506206	CS
4	3.88	26.0228034876	14.91	18.85	14.4669	372985	16.29260287	CS
12	1.62	9.43506115317	17.17	19.725	13.715	277294	16.10617906	CS
26	4.57	32.1378340366	14.22	22.188	13.715	240298	16.73907964	CS
52	9.13	94.5134575569	9.66	22.188	8.389	162976	15.56113336	CS
156	-4.96	-20.8842105263	23.75	23.75	4.81	94825	13.73794998	CS
260	-4.62	-19.7351559163	23.41	33.01	4.03	85455	16.33072841	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
SHOTWSafety Shot Inc	$ 0.41 (115.79%)	7.56k
DATSDatChat Inc	$ 1.89 (81.73%)	54.75M
CYNCYNGN Inc	$ 9.18 (53.77%)	17.79M
SCNIScinai Immunotherapeutics Ltd	$ 5.80 (42.86%)	29.37M
ASLNASLAN Pharmaceuticals Ltd	$ 1.36 (-46.67%)	1.16M
KZIAKazia Therapeutics Ltd	$ 0.5593 (-37.56%)	15.34M
LCFYLocafy Ltd	$ 3.5597 (-36.32%)	584.38k
NAASNaaS Technology Inc	$ 2.82 (-33.02%)	1.94M
ZENVZenvia Inc	$ 1.67 (-26.75%)	658.26k
FFIEFaraday Future Intelligent Electric Inc	$ 0.5152 (22.09%)	217.92M
NVDANVIDIA Corporation	$ 128.44 (-0.62%)	208.32M
SQQQProShares UltraPro Short QQQ	$ 7.46 (-0.67%)	155.14M
AMIXAutonomix Medical Inc	$ 1.3701 (121.70%)	154.81M
TSLATesla Inc	$ 252.64 (1.78%)	147.31M